1. Home
  2. ADAG vs CRT Comparison

ADAG vs CRT Comparison

Compare ADAG & CRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADAG
  • CRT
  • Stock Information
  • Founded
  • ADAG 2011
  • CRT 1991
  • Country
  • ADAG China
  • CRT United States
  • Employees
  • ADAG N/A
  • CRT N/A
  • Industry
  • ADAG Biotechnology: Pharmaceutical Preparations
  • CRT Oil & Gas Production
  • Sector
  • ADAG Health Care
  • CRT Energy
  • Exchange
  • ADAG Nasdaq
  • CRT Nasdaq
  • Market Cap
  • ADAG 76.3M
  • CRT 65.1M
  • IPO Year
  • ADAG 2021
  • CRT 1992
  • Fundamental
  • Price
  • ADAG $1.90
  • CRT $9.79
  • Analyst Decision
  • ADAG Strong Buy
  • CRT
  • Analyst Count
  • ADAG 1
  • CRT 0
  • Target Price
  • ADAG $8.00
  • CRT N/A
  • AVG Volume (30 Days)
  • ADAG 75.3K
  • CRT 26.8K
  • Earning Date
  • ADAG 07-24-2025
  • CRT 01-01-0001
  • Dividend Yield
  • ADAG N/A
  • CRT 9.24%
  • EPS Growth
  • ADAG N/A
  • CRT N/A
  • EPS
  • ADAG N/A
  • CRT 0.99
  • Revenue
  • ADAG $103,204.00
  • CRT $6,834,116.00
  • Revenue This Year
  • ADAG $6,488.89
  • CRT N/A
  • Revenue Next Year
  • ADAG $57.50
  • CRT N/A
  • P/E Ratio
  • ADAG N/A
  • CRT $10.08
  • Revenue Growth
  • ADAG N/A
  • CRT N/A
  • 52 Week Low
  • ADAG $1.33
  • CRT $8.88
  • 52 Week High
  • ADAG $3.58
  • CRT $13.31
  • Technical
  • Relative Strength Index (RSI)
  • ADAG 52.47
  • CRT 44.17
  • Support Level
  • ADAG $1.73
  • CRT $9.95
  • Resistance Level
  • ADAG $2.02
  • CRT $10.38
  • Average True Range (ATR)
  • ADAG 0.15
  • CRT 0.25
  • MACD
  • ADAG -0.01
  • CRT 0.03
  • Stochastic Oscillator
  • ADAG 42.50
  • CRT 45.38

About ADAG Adagene Inc.

Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.

About CRT Cross Timbers Royalty Trust

Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.

Share on Social Networks: